Blood Advances

Article	Citations
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism	601
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer	403
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19	299
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma	259
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma	235
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease	233
A neutrophil activation signature predicts critical illness and mortality in COVID-19	218
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma	218
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults	196
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma	189
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab	186
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain	171
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies	157
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease	144
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma	133
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma	130
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML	122
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub	119
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing	119
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients	118
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma	118
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features	114
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19	113
Reduced prevalence of SARS-CoV-2 infection in ABO blood group O	112
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1	111

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma	110
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults	105
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia	101
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML	100
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML	99
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations	99
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens	98
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19	94
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide	92
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease	91
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease	90
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT	89
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	89
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia	88
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma	88
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19	87
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML	85
Gilteritinib: potent targeting of FLT3 mutations in AML	85
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge	84
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML	84
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	83
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura	78
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure	77
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data	76
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A	76
Next-generation cell therapies: the emerging role of CAR-NK cells	74
The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma	73
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial	72
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality	72
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients	70
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation	69
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study	67
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis	67
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma	66
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States	66
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease	66
Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia	65
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis	65
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease	65
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma	63
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma	63
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies	62
Survival following allogeneic transplant in patients with myelofibrosis	61
Single-cell mutational profiling enhances the clinical evaluation of AML MRD	61
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML	60
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study	60
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis	60
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma	60
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations	60
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy	59

BiTEs better than CAR T cells	58
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial	58
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma	58
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis	58
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma	58
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy	58
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia	58
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms	58
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia	58
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection	57
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide	57
Inflammasome activation in neutrophils of patients with severe COVID-19	57
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells	57
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity	57
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up	57
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort	55
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia	55
Fedratinib in myelofibrosis	55
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial	54
Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity	54
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis	54
Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match	53
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals	53
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma	53
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects	53
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas	53
High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential	53
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities	53
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma	52
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents	52
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome	52
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells	51
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial	51
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies	51
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults	50
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia	50
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19	50
Artificial intelligence–based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients	50
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice	49
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis	49
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features	48
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results	48
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells	48
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma	48
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification	48
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease	47
Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia	47
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination	47
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study	47
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)	47
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm	46
The incidence of cancer-associated thrombosis is increasing over time	46
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model	45
COVID-19 coagulopathy vs disseminated intravascular coagulation	45
Lung megakaryocytes display distinct transcriptional and phenotypic properties	45
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients	45
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy	45
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy	45
Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma	45
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes	45
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis	45
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy	45
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data	45
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles	45
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells	44
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP	43
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP	43
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial	43
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?	43
Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity	43
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication	43
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy	43
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant	42
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in	42
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL	42
Cell interactions in the bone marrow microenvironment affecting myeloid malignancies	42
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients	42
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase	42
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma	41
Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy	41

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years	41
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML	41
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)	41
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma	41
Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation	41
Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients	41
Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice	40
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19	40
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients	40
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma	40
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes	40
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies	40
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells	40
CAR T-cell therapy for secondary CNS DLBCL	40
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis	39
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings	39
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	39
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation	39
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting	39
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study	39
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models	39
Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling	39
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia	39
Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects	39
Interferon-complement loop in transplant-associated thrombotic microangiopathy	39
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure	38
High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers	38
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation	38
Mesenchymal stromal cells in hematopoietic cell transplantation	38
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation	38
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition	38
Development of luspatercept to treat ineffective erythropoiesis	38
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma	38
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms	38
Lingering effects of chemotherapy on mature T cells impair proliferation	38
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia	38
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis	38
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies	38
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing	37
Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes	37
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure	37
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome	37
Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism	37
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation	37
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy	37
Laboratory monitoring of hemophilia A treatments: new challenges	37
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium	36
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis	36
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma	36
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia	36
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse	36
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma	36
Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells	36
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors	36
Inflammasome activation promotes venous thrombosis through pyroptosis	36
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern	36
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide	36
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734	35
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer	35
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity	35
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19	35
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation	35
Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions	35
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia	35
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents	34
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition	34
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up	34
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia	34
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia	34
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant	34
First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG	34
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis	34
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases	34
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2	34
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma	34
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia	34
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)	34
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax	34
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial	33
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis	33
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery	33
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias	33
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation	33
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma	33
Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis	33
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia	33
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia	33
Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden	33
Suboptimal iron deficiency screening in pregnancy and the impact of socioeconomic status in a high-resource setting	32
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation	32
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia	32
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study	32
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial	32
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study	32
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	32